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1. Introduction
Recent advances in molecular biology combined with the culmination of the Human Ge‐
nome Project [1] have provided a genetic understanding of cellular processes and disease
pathogenesis; numerous genes involved in disease and cellular processes have been identi‐
fied as targets for therapeutic approaches. In addition, the development of high-throughput
screening techniques (e.g., cDNA microarrays, differential display and database meaning)
may drastically increase the rate at which these targets are identified [2,3]. Over the past
years there has been a remarkable expansion of both the number of human genes directly
associated with disease states and the number of vector systems available to express those
genes for therapeutic purposes. However, the development of novel therapeutic strategies
using these targets is dependent on the ability to manipulate the expression of these target
genes in the desired cell population. In this chapter we explain the concept and aim of gene
therapy, the different gene delivery systems and therapeutic strategies, how genes are deliv‐
ered and how they reach the target.
2. Aim and concept of gene therapy with non-viral vectors
A gene therapy medicinal product is a biological product which has the following character‐
istics: (a) it contains an active substance which contains or consists of a recombinant nucleic
acid used in administered to human beings with a view to regulating, repairing, replacing,
adding or deleting a genetic sequence; (b) its therapeutic, prophylactic or diagnostic effect
relates directly to the recombinant nucleic acid sequence it contains, or to the product of ge‐
netic expression of this sequence [4].
© 2013 Gascón et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The most important, and most difficult, challenge in gene therapy is the issue of delivery.
The tools used to achieve gene modification are called gene therapy vectors and they are the
“key” for an efficient and safe strategy. Therefore, there is a need for a delivery system,
which must first overcome the extracellular barriers (such as avoiding particle clearance
mechanisms, targeting specific cells or tissues and protecting the nucleic acid from degrada‐
tion) and, subsequently, the cellular barriers (cellular uptake, endosomal escape, nuclear en‐
try and nucleic release) [5]. An ideal gene delivery vector should be effective, specific, long
lasting and safe.
Gene therapy has long been regarded a promising treatment for many diseases, including
inherited through a genetic disorder (such as hemophilia, human severe combined immuno‐
deficiency, cystic fibrosis, etc) or acquired (such as AIDS or cancer). Figures 1 and 2 show
the indications addressed and the gene types transferred in gene therapy clinical trials, re‐
spectively [6].
Indications addressed by gene therapy clinical trials
Cancer diseases
Cardiovascular diseases
Gene marking
Healthy volunteers
Infectious diseases
Inflammatory diseases
Monogenic diseases
Neurological diseases
Ocular diseases
Others
Figure 1. Indications addressed by gene therapy clinical trials (adapted from http://www.wiley.co.k/genmed/clinical).
Gene delivery systems include viral vectors and non-viral vectors. Viral vectors are the most
effective, but their application is limited by their immunogenicity, oncogenicity and the
small size of the DNA they can transport. Non-viral vectors are safer, of low cost, more re‐
producible and do not present DNA size limit. The main limitation of non-viral systems is
their low transfection efficiency, although it has been improved by different strategies and
the efforts are still ongoing [6]; actually, advances of non-viral delivery have lead to an in‐
creased number of products entering into clinical trials. However, viral vector has dominat‐
ed the clinical trials in gene therapy for its relatively high delivery efficiency. Figure 3 shows
the proportion of vector systems currently in human trials [7].
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Gene types  trasnferred in gene therapy clinical trials
Adhesion molecule
Antigen
Antisense
Cell cycle
Cell protection/Drug resistance
Cytokine
Deficiency
Grow th factor
Hormone
Marker
Oncogene regulator
Oncolytic virus
Porins, ion channels, transporters
Receptor
Replication inhibitor
Ribozyme
siRNA
Suicide
Transcription factor
Tumor suppressor
Viral vaccine
Others
Unknow n
Figure 2. Gene types transferred in gene therapy clinical trials (adapted from http://www.wiley.co.k/genmed/clinical).
Vectors used for gene therapy clinical trials
Adennovirus
Retrovirus
Naked/plasmid DNA
Vaccinia virus
Lipofection 
Poxvirus
Adeno-associated virus
Herpex simplex virus
Lentivirus
Other categories
Unknown
Figure 3. Vector systems used in gene therapy clinical trials (adapted from http://www.wiley.co.k/genmed/clinical).
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3. Non-viral methods for transfection
Currently, three categories of non-viral systems are available:
• Inorganic particles
• Synthetic or natural biodegradable particles
• Physical methods
Table 1 summarizes the most utilized non-viral vectors.
Category System for gene delivery
Inorganic particles Calcium phosphate
Silica
Gold
Magnetic
Synthetic or natural biodegradable particles 1. Polymeric-based non-viral vectors:
Poly(lactic-co-glycolic acid) (PLGA)
Poly lactic acid (PLA)
Poly(ethylene imine) (PEI)
Chitosan
Dendrimers
Polymethacrylates
2. Cationic lipid-based non-viral vectors:
Cationic liposomes
Cationic emulsions
Solid lipid nanoparticles
3. Peptide-based non-viral vectors:
Poly-L-lysine
Other peptides to functionalize other delivery systems: SAP, protamine
Physical methods Needle injection
Balistic DNA injection
Electroporation
Sonoporation
Photoporation
Magnetofection
Hydroporation
Table 1. Delivery systems for gene therapy.
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3.1. Inorganic particles
Inorganic nanoparticles are nanostructures varying in size, shape and porosity, which can
be engineered to evade the reticuloendothelial system or to protect an entrapped molecular
payload from degradation or denaturation [8]. Calcium phosphate, silica, gold, and several
magnetic compounds are the most studied [9-11]. Silica-coated nanoparticles are biocompat‐
ible structures that have been used for various biological applications including gene thera‐
py due to its biocompatibility [8]. Mesoporous silica nanoparticles have shown gene
transfection efficiency “in vitro” in glial cells [12]. Magnetic inorganic nanoparticles (such as
Fe3O4, MnO2) have been applied for cancer-targeted delivery of nucleic acids and simultane‐
ous diagnosis via magnetic resonance imaging [13,14]. Silica nanotubes have been also stud‐
ied as an efficient gene delivery and imaging agent [13].
Inorganic particles can be easily prepared and surface-functionalized. They exhibit good
storage stability and are not subject to microbial attack [13]. Bhattarai et al. [15] modified
mesoporous silica nanoparticles with poly(ethylene glycol) and methacrylate derivatives
and used them to deliver DNA or small interfering RNA (siRNA) “in vitro”.
Gold nanoparticles have been lately investigated for gene therapy. They can be easily pre‐
pared, display low toxicity and the surface can be modified using various chemical techni‐
ques [16]. For instance, gold nanorods have been proposed to deliver nucleic acids to tumors
[13]. They have strong absorption bands in the near-infrared region, and the absorbed light
energy is then converted into heat by gold nanorods (photohermal effect). The near-infrared
light can penetrate deeply into tissues; therefore, the surface of the gold could be modified
with double-stranded DNA for controlled release [17]. After irradiation with near-infrared
light, single stranded DNA is released due to thermal denaturation induced by the photo‐
thermal effect.
3.2. Synthetic or natural biodegradable particles
Synthetic or natural biocompatible particles may be composed by cationic polymers, cationic
lipids or cationic peptides, and also the combination of these components [18-21]. The poten‐
tial advantages of biodegradable carriers are their reduced toxicity (degradation leads to
non-toxic products) and avoidance of accumulation of the polymer in the cells.
3.2.1. Polymer-based non-viral vectors
Cationic polymers condense DNA into small particles (polyplexes) and prevent DNA from
degradation. Polymeric nanoparticles are the most commonly used type of nano-scale deliv‐
ery systems. They are mostly spherical particles, in the size range of 1-1000 nm, carrying the
nucleic acids of interest. DNA can be entrapped into the polymeric matrix or can be adsor‐
bed or conjugated on the surface of the nanoparticles. Moreover, the degradation of the pol‐
ymer can be used as a tool to release the plasmid DNA into the cytosol [22]. Table 1 shows
several commonly used polymers used for gene delivery [16].
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3.2.1.1. Poly(lactic-co-glycolic acid) (PLGA) and poly lactic acid (PLA)
Biodegradable polyesters, PLGA and PLA, are the most commonly used polymers for deliv‐
ering drugs and biomolecules, including nucleic acids. They consist of units of lactic acid
and glycolic acid connected through ester linkage. These biodegradable polymers undergo
bulk hydrolysis thereby providing sustained delivery of the therapeutic agent. The degrada‐
tion products, lactic acid and glycolic acid, are removed from the body through citric acid
cycle. The release of therapeutic agent from these polymers occurs by diffusion and polymer
degradation [16].
PLGA has a demonstrated FDA approved track record as a vehicle for drug and protein de‐
livery [23,24]. Biodegradable PLA and PLGA particles are biocompatible and have the ca‐
pacity to protect pDNA from nuclease degradation and increase pDNA stability [25,26].
PLGA particles typically less than 10 µm in size are efficiently phagocytosed by professional
antigen presenting cells; therefore, they have significant potential for immunization applica‐
tions [27,28]. For example, intramuscular immunization of p55 Gag plasmid adsorbed on
PLGA/cetyl trimethyl ammonium bromide (CTAB) particles induced potent antibody and
cytotoxic T lymphocyte responses. These particles showed a 250-fold increase in antibody
response at higher DNA doses and more rapid and complete seroconversion, at the lower
doses, compared to other adjuvants, including cationic liposomes [29].
The encapsulation efficiency of DNA in PLGA nanoparticles is not very high, and it de‐
pends on the molecular weight of the PLGA and on the hydrophobicity of the polymer, be‐
ing the hydrophilic polymers those that provide higher loading efficiency [30]. To enhance
the DNA loading, several strategies have been proposed. Kusonowiriyawong et al. [31] pre‐
pared cationic PLGA microparticles by dissolving cationic surfactants (like water insoluble
stearylamine) in the organic solvent in which the PLGA was dissolved to prepare the micro‐
particles. Another strategy was to reduce the negative charge of plasmid DNA by condens‐
ing it with poly(aminoacids) (like poly-L-lysine) before encapsulation in PLGA
microparticles [32,33].
Normally, after an initial burst release, plasmid DNA release from PLGA particles occurs
slowly during several days/weeks [22]. The degradation of the PLGA nanoparticles, through
a bulk homogeneous hydrolytic process, determines the release of plasmid DNA. Conse‐
quently, it can be expected that the use of more hydrophilic PLGA not only improves the
encapsulation efficiency of DNA, but also results in a faster release of plasmid DNA. Deliv‐
ery of the plasmid DNA depends on the copolymer composition of the PLGA (lactic acid
versus glycolic acid), molecular weight, particle size and morphology [22]. DNA release ki‐
netics depends also on the plasmid incorporation technique; Pérea et al. [34] reported that
nanoparticles prepared by the water-oil emulsion/diffusion technique released their content
rapidly, whereas those obtained by the water-oil-emulsion method showed an initial burst
followed by a slow release during at least 28 days.
PLGA and PLA based nanoparticles have also been used for “in vitro” RNAi delivery [35].
For instance, Hong et al. [36] have shown the effects of glucocorticoid receptor siRNA deliv‐
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ered using PLGA microparticles, on proliferation and differentiation capabilities of human
mesenchymal stromal cells.
3.2.1.2. Chitosan
Chitosan [b(1-4)2-amino-2-deoxy-D-glucose] is a biodegradable polysaccharide copolymer
of N-acetyl-D-glucosamine and D-glucosamine obtained by the alkaline deacetylation of chi‐
tin, which is a polysaccharide found in the exoskeleton of crustaceans of marine arthropods
and insects [37]. Chitosans differ in the degree of N-acetylation (40 to 98%) and molecular
weight (50 to 2000 kDa) [38]. As the only natural polysaccharide with a positive charge, chi‐
tosan has the following unique properties as carrier for gene therapy:
• it is potentially safe and non-toxic, both in experimental animals [39] and humans [40]
• it can be degraded into H2O and CO2 in the body, which ensures its biosafety
• it has biocompatibility to the human body and does not elicit stimulation of the mucosa
and the derma
• its cationic polyelectrolyte nature provides a strong electrostatic interaction with nega‐
tively charged DNA [41], and protects the DNA from nuclease degradation [42]
• the mucoadhesive property of chitosan potentially leads to a sustained interaction be‐
tween the macromolecule being “delivered” and the membrane epithelia, promoting
more efficient uptake [43]
• it has the ability to open intercellular tight junctions, facilitating its transport into the cells
[44]
Currently, there is a commercial transfection reagent based on chitosan (Novafect, NovaMa‐
trix, FMC, US), and many other prototypes are under development. Most of the chitosan-
based nanocarriers for gene delivery have been based on direct complexation of chitosan
and the nucleic acid [45], whereas in some instances additional polyelectrolytes, polymers
and lipids have been used in order to form composite nanoparticles [46-49] or chitosan-coat‐
ed hydrophobic nanocarriers.
Many studies using cell cultures have shown that pDNA-loaded chitosan nanocarriers are
able to achieve high transfection levels in most cell lines [50]. Chitosan nanocarriers loaded
with siRNA have provided gene suppression values similar to the commercial reagent lipo‐
fectamine [51,52,18,53].
Chitosan of low molecular weight is more efficient for transfection than chitosan with high
molecular weight. This enhancement in transfection efficacy observed with low molecular
weight chitosan can be attributed to the easier release of pDNA from the nanocarrier upon
cell internalization. Moreover, the presence of free low molecular chitosan has been deemed
to be very important for the endosomal escape of the nanocarriers [50]. Concerning deacety‐
lation degree, its influence on transfection is not still clear. “In vitro” studies have shown
that the best transfection is achieved with highly deacetylated chitosan [54,55]. However, “in
Non-Viral Delivery Systems in Gene Therapy
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vivo”, higher transfection was achieved after intramuscular administration of chitosan com‐
plexes with a low deacetylation degree [55].
3.2.1.3. Poly(ethylene imine) (PEI)
PEI is one of the most potent polymers for gene delivery. PEI is produced by the polymeri‐
zation of aziridine and has been used to deliver genetic material into various cell types both
“in vitro” and “in vivo” [56,57]. There are two forms of this polymer: the linear form and the
branched form, being the branched structure more efficient in condensing nucleic acids than
the linear PEI [58].
PEI has a high density of protonable amino groups, every third atom being amino nitrogen,
which imparts a high buffering ability at practically any pH [16]. Hence, once inside the en‐
dosome, PEI disrupts the vacuole releasing the genetic material in the cytoplasm. This abili‐
ty to escape from the endosome, as well as the ability to form stable complexes with nucleic
acids, make this polymer very useful as a gene delivery vector [56].
Depending on the type of polymer (e.g. linear or branched PEI), as well as the molecular
weight, the particle sizes of the polyplexes formed are more or less uniformly distributed
[59]. Transfection efficiency of PEI has been found to be dependent on a multitude of factors
such as molecular weight, degree of branching, N/P ratio, complex size, etc [60].
The use of PEI for gene delivery is limited due to the relatively low transfection efficiency,
short duration of gene expression, and elevated toxicity [61,62]. Conjugation of poly(ethyl‐
ene glycol) to PEI to form diblock or triblock copolymers has been used by some authors to
reduce the toxicity of PEI [63,64,65]. Poly(ethylene glycol) also shields the positive charge of
the polyplexes, thereby providing steric stability to the complex. Such stabilization prevents
non-specific interaction with blood components during systemic delivery [66].
3.2.1.4. Dendrimes
Dendrimers are polymer-based molecules with a symmetrical structure in precise size and
shapes, as well as terminal group functionality [8]. Dendrimers contain three regions: i) a
central core (a single atom or a group of atoms having two or more identical chemical fun‐
cionalities); ii) branches emanating from core, which are composed of repeating units with
at least one branching junction, whose repetition is organized in a geometric progression
that results in a series of radially concentric layers; and iii) terminal function groups. Den‐
drimers bind to genetic material when peripheral groups, that are positively-charged at
physiological pH, interact with the negatively-charged phosphate groups of the nucleic acid
[67,68]. Due to their nanometric size, dendrimers can interact effectively and specifically
with cell components such as membranes, organelles, and proteins [69].
For instance, Qi et al. [70] showed the ability of generations 5 and 6 (G5 and G6) of
poly(amidoamine) (PAMAM) dendrimers, conjugated with poly(ethylene glycol) to effi‐
ciently transfect both “in vitro” and “in vivo” after intramuscular administration to neonatal
mice. PAMAM has also the ability to deliver siRNAs, especially “in vitro” in cell culture sys‐
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tems [71-73]. Recent studies showed that the dendrimer-mediated siRNA delivery and gene
silencing depends on the stoichiometry, concentration of siRNA and the dendrimer genera‐
tion [71]. In a recent study, a PAMAM dendrimer-delivered short hairpin RNA (shRNA)
showed the ability to deplect a human telomerase reverse transcriptase, the catalytic subunit
of telomerase complex, resulting in partial cellular apoptosis, and inhibition of tumor out‐
growth in xenotransplanted mice [74].
The toxicity profile of dendrimers is good, although it depends on the number of terminal
amino groups and positive charge density. Moreover, toxicity is concentration and genera‐
tion dependent with higher generations being more toxic as the number of surface groups
doubles with increasing generation number [75,76].
3.2.1.5. Polymethacrylates
Polymethacrylates are cationic vinyl-based polymers that possess the ability to condense
polynucleotides into nanometer size particles. They efficiently condense DNA by forming
inter-polyelectrolyte complexes. A range of polymethacrylates, differing in molecular
weights and structures, have been evaluated for their potential as gene delivery vector, such
us poly[2-dimethylamino) ethyl methacrylate] (DMAEMA) and its co-polymers [16]. The
use of polymethactrtylates for DNA transfection is, however, limited due to their low ability
to interact with membranes.
In order to optimise the use of these compounds for gene transfer, Christiaens et al. [77]
combined polymethacrylates with penetratin, a 16-residue water-soluble peptide that inter‐
nalises into cells through membrane translocation. Penetratin mainly enhanced the endoly‐
sosomal escape of the polymethacrylate–DNA complexes and increased their cellular uptake
using COS-1 (kidney cells of the African green monkey). Nanoparticles with a methacrylate
core and PEI shell prepared via graft copolymerization have also been employed lately for
gene delivery [78,79]. This conjugation resulted in nanoparticles with a higher transfection
efficiency and lower toxicity as compared with PEI.
3.2.2. Cationic-lipid based non-viral vectors
Cationic lipids have been among the more efficient synthetic gene delivery reagents “in vi‐
tro” since the landmark publications in the late 1980s [80]. Cationic lipids can condense nu‐
cleic acids into cationic particles when the components are mixed together. This cationic
lipid/nucleic acid complex (lipoplex) can protect nucleic acids from enzymatic degradation
and deliver the nucleic acids into cells by interacting with the negatively charged cell mem‐
brane [81]. Lipoplexes are not an ordered DNA phase surrounded by a lipid bilayer; rather,
they are a partially condensed DNA complex with an ordered substructure and an irregular
morphology [82,83]. Since the initial studies, hundreds of cationic lipids have been synthe‐
sized as candidates for non-viral gene delivery [84] and a few made it to clinical trials
[85,86].
Cationic lipids can be used to form lipoplexes by directly mixing the positively charged lip‐
ids at the physiological pH with the negatively charged DNA. However, cationic lipids are
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more frequently used to prepare lipoplex structures such as liposomes, nanoemulsions or
solid lipid nanoparticles [81].
3.2.2.1. Cationic liposomes
Liposomes are spherical vesicles made of phospholipids used to deliver drugs or genes.
They can range in size from 20 nm to a few microns. Cationic liposomes and DNA interact
spontaneously to form complexes with 100% loading efficiency; in other words, all of the
DNA molecules are complexed with the liposomes, if enough cationic liposomes are availa‐
ble. It is believed that the negative charges of the DNA interact with the positively charged
groups of the liposomes [87]. The lipid to DNA ratio, and overall lipid concentration used in
forming these complexes, are very important for efficient gene delivery and vary with appli‐
cations [88].
Liposomes offer several advantages for gene delivery [87]:
• they are relatively cheap to produce and do not cause diseases
• protection of the DNA from degradation, mainly due to nucleases
• they can transport large pieces of DNA
• they can be targeted to specific cells or tissues
Successful delivery of DNA and RNA to a variety of cell types has been reported, including
tumour, airway epithelial cells, endothelial cells, hepatocytes, muscle cells and others, by in‐
tratissue or intravenous injection into animals [89,90].
Several liposome-based vectors have been assayed in a number of clinical trials for cancer
treatment. For instance, Allovectin-7® (Vical, San Diego, CA, USA), a plasmid DNA carrying
HLAB and ß2-microglobulin genes complexed with DMRIE/DOPE liposomes have been as‐
sessed for safety and efficacy in phase I and II clinical trials [91,92].
3.2.2.2. Lipid nanoemulsions
An emulsion is a dispersion of one immiscible liquid in another stabilized by a third compo‐
nent, the emulsifying agent [93]. The nanoemulsion consists of oil, water and surfactants,
and presents a droplet size distribution of around 200 nm. Lipid-based carrier systems rep‐
resent drug vehicles composed of physiological lipids, such as cholesterol, cholesterol esters,
phospholipids and tryglicerides, and offer a number of advantages, making them an ideal
drug delivery carrier [94]. Adding cationic lipids as surfactants to these dispersed systems
makes them suitable for gene delivery. The presence of cationic surfactants, like DOTAP,
DOTMA or DC-Chol, causes the formation of positively charged droplets that promote
strong electrostatic interactions between emulsion and the anionic nucleic acid phosphate
groups [95,96]. For instance, Bruxel et al. [97] prepared a cationic nanoemulsion with DO‐
TAP as a delivery system for oligonucleotides targeting malarial topoisomerase II.
Lipid emulsions are considered to be superior to liposomes mainly in a scaling-up point of
view. On the one hand, emulsions can be produced on an industrial scale; on the other
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hand, emulsions are stable during storage and are highly biocompatible [94]. In addition,
the physical characteristics and serum-resistant properties of the DNA/nanoemulsion com‐
plexes suggest that cationic nanoemulsions could be a more efficient carrier system for gene
and/or immunogene delivery than liposomes. One of the reasons for the serum-resistant
properties of the cationic lipid nanoemulsions may be the stability of the
nanoemulsion/DNA complex [98]. However, in spite of extensive research on emulsions,
very few reports using cationic amino-based nanoemulsions in gene delivery have been
published. After “in vivo” administration, cationic nanoemulsions have shown higher trans‐
fection and lower toxicity than liposomes [99].
The incorporation of noninonic surfactant with a branched poly(ethylene glycol), such as
Tween 80®, increments the stability of the nanoemulsion and prevent the formation of large
nanoemulsion/DNA complexes, probably because of their stearic hindrance and the genera‐
tion of a hydrophilic surface that may enhance the stability by preventing physical aggrega‐
tion [94]. In addition, this strategy may prevent from enzymatic degradation in blood, and
due to the hydrophilic surface, they are taken up slowly by phagocytic cells, resulting in
prolonged circulation in blood [100,101].
3.2.2.3. Solid lipid nanoparticles (SLN)
Solid lipid nanoparticles are particles made from a lipid being solid at room temperature
and also at body temperature. They combine advantages of different colloidal systems. Like
emulsions or liposomes, they are physiologically compatible and, like polymeric nanoparti‐
cles, it is possible to modulate drug release from the lipid matrix. In addition, SLN possess
certain advantages. They can be produced without use of organic solvents, using high pres‐
sure homogenization (HPH) method that is already successfully implemented in pharma‐
ceutical industry [102]. From the point of view of application, SLN have very good stability
[103] and are subject to be lyophilized [104], which facilitates the industrial production.
Cationic SLN, for instance, SLN containing at least one cationic lipid, have been proposed as
non-viral vectors for gene delivery [105,20]. It has been shown that cationic SLN can effec‐
tively bind nucleic acids, protect them from DNase I degradation and deliver them into liv‐
ing cells. Cationic lipids are used in the preparation of SLN applied in gene therapy not only
due to their positive surface charge, but also due to their surfactant activity, necessary to
produce an initial emulsion, which is a common step in most preparation techniques. By
means of electrostatic interactions, cationic SLN condense nucleic acids on their surface,
leading generally to an excess of positive charges in the final complexes. This is beneficial
for transfection because condensation facilitates the mobility of nucleic acids, protects them
from environmental enzymes and the cationic character of the vectors allows the interaction
with negatively charged cell surface. The characteristics of the resulting complexes depend
on the ratio between particle and nucleic acid; there must be an equilibrium between the
binding forces of the nucleic acids to SLN to achieve protection without hampering the pos‐
terior release in the site of action [106]. Release of DNA from the complexes may be one of
the most crucial steps determining the optimal ratio for cationic lipid system-mediated
transfection [107].
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Our research group showed for the first time the expression of a foreign protein with SLNs
in an “in vivo” study [108]. After intravenous administration of SLN containing the EGFP
plasmid to BALB/c mice, protein expression was detected in the liver and spleen from the
third day after administration, and it was maintained for at least 1 week. In a later study
[109], we incorporated dextran and protamine in the SLN and the transfection was im‐
proved, being detected also in lung. The improvement in the transfection was related to a
longer circulation in the bloodstream due to the presence of dextran on the nanoparticle sur‐
face. The surface features of this new vector may also induce a lower opsonization and a
slower uptake by the RES. Moreover, the high DNA condensation of protamine that contrib‐
utes to the nuclease resistance may result in an extended stay of plasmid in the organism.
The presence of nuclear localization signals in protamine, which improves the nuclear enve‐
lope translocation, and its capacity to facilitate transcription [110] may also explain the im‐
provement of the transfection efficacy “in vivo”.
SLN have also been applied for the treatment of ocular diseases by gene therapy. After ocu‐
lar injection of a SLN based vector to rat eyes, the expression of EGFP was detected in vari‐
ous types of cells depending on the administration route: intravitreal or subretinal. In
addition, this vector was also able to transfect corneal cells after topical application [111].
SLN may also be used as delivery systems for siRNA or oligonucleotides. Apolipoprotein-
free low-density lipoprotein (LDL) mimicking SLN [112] formed stable complexes with siR‐
NA and exhibited comparable gene silencing efficiency to siRNA complexed with the
polymer PEI, and lower citotoxicity. Afterwards, Tao et al. [113] showed that lipid nanopar‐
ticles caused 90% reduction of luciferase expression for at least 10 days, after a single sys‐
temic administration of 3 mg/kg luciferase siRNA to a liver-luciferase mouse model. CTAB
stabilized SLN bearing an antisense oligonucleotide against glucosylceramide synthase
(asGCS) reduced the viability of the drug resistant NCI/ADR-RES human ovary cancer cells
in the presence of the chemotherapeutic doxorubicin [114].
3.2.3. Peptide-based gene non-viral vectors
Many types of peptides, which are generally cationic in nature and able to interact with
plasmid DNA through electrostatic interaction, are under intense investigation as a safe al‐
ternative for gene therapy [115]. There are mainly four barriers that must be overcome by
non-viral vectors to achieve successful gene delivery. The vector must be able to tightly
compact and protect DNA, target specific cell-surface receptors, disrupt the endosomal
membrane, and deliver the DNA cargo to the nucleus [115]. Peptide-based vectors are ad‐
vantageous over other non-viral systems because they are able to achieve all of these goals
[116]. Cationic peptides rich in basic residues such as lysine and/or arginine are able to effi‐
ciently condense DNA into small, compact particles that can be stabilized in serum
[117,118]. Attachment of a peptide ligand to a polyplex or lipoplex allows targeting to spe‐
cific receptors and/or specific cell types. Peptide sequence derived from protein transduction
domains are able to selectively lyse the endosomal membrane in its acidic environment lead‐
ing to cytoplasmic release of the particle [119,120]. Finally, short peptide sequences taken
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from longer viral proteins can provide nuclear localization signals that help the transport of
the nucleic acids to the nucleus [121,122].
3.2.3.1. Poly-L-lysine
Poly-L-lysine is a biodegradable peptide synthesized by polimerization on N-carboxy-anhy‐
dride of lysine [123]. It is able to form nanometer size complexes with polynucleotides ow‐
ing to the presence of protonable amine groups on the lysine moiety [16]. The most
commonly used poly-L-lysine has a polymerization degree of 90 to 450 [124]. This character‐
istic makes this peptide suitable for “in vivo” use because it is readily biodegradable [116].
However, as the length of the poly-L-lysine increases, so does the cytotoxicity. Moreover,
poly-L-lysine exhibits modest transfection when used alone and requires the addition of an
edosomolytic agent such as chloroquine or a fusogenic peptide to allow for release into the
cytoplasm. An strategy to prevent plasma protein binding and increase circulation half-life
is the attachment of poly(ethylene glycol) to the poly-L-lysine [125,126].
3.2.3.2. Peptides in multifunctional delivery systems
Due to the advantages of peptides for gene delivery, they are frequently used to funtionalize
cationic lipoplexes or polyplexes. Since these vectors undergo endocytosis, decorating them
with endosomolytic peptides for enhanced cytosolic release may be helpful. Moreover, com‐
bination with peptides endowed with the ability to target a specific tissue of interest is high‐
ly beneficial, since this allows for reduced dose and, therefore, reduced side effects
following systemic administration [127]. In a study carried out by our group [19], we im‐
proved cell transfection of ARPE-19 cells by using a cell penetration peptide (SAP) with sol‐
id lipid nanoparticles. Kwon et al. [128] covalently attached a truncated endosomolytic
peptide derived from the carboxy-terminus of the HIV cell entry protein gp41 to a PEI scaf‐
fold, obtaining improved gene transfection results compared with unmodified PEI. In other
study [20], protamine induced a 6-fold increase in the transfection capacity of SLN in retinal
cells due to a shift in the internalization mechanism from caveolae/raft-mediated to clathrin-
mediated endocytosis, which promotes the release of the protamine-DNA complexes from
the solid lipid nanoparticles; afterwards the transport of the complexes into the nucleus is
favoured by the nuclear localization signals of the protamine.
3.3. Physical methods for gene delivery
Gene delivery using physical principles has attracted increasing attention. These methods
usually employ a physical force to overcome the membrane barrier of the cells and facilitate
intracellular gene transfer. The simplicity is one of the characteristics of these methods. The
genetic material is introduced into cells without formulating in any particulate or viral sys‐
tem. In a recent publication, Kamimura et al. [87] revised the different physical methods for
gene delivery. These methods include the following:
Non-Viral Delivery Systems in Gene Therapy
http://dx.doi.org/10.5772/52704
15
3.3.1. Needle injection
The DNA is directly injected through a needle-carrying syringe into tissues. Several tissues
have been transfected by this method [87]: muscle, skin, liver, cardiac muscle, and solid tu‐
mors. DNA vaccination is the major application of this gene delivery system [129]. The effi‐
ciency of needle injection of DNA is low; moreover, transfection is limited to the needle
surroundings.
3.3.2. Ballistic DNA injection
This method is also called particle bombardment, microprojectile gene transfer or gene gun.
DNA-coated gold particles are propelled against cells, forcing intracellular DNA transfer.
The accelerating force for DNA-containing particles can be high-voltage electronic dis‐
charge, spark discharge or helium pressure discharge. One advantage of this method is that
it allows delivering precise DNA doses. However, genes express transiently, and considera‐
ble cell damage occurs at the centre of the discharge site. This method has been used in vac‐
cination against the influenza virus [130] and in gene therapy for treatment of ovarian
cancer [131].
3.3.3. Electroporation
Gene delivery is achieved by generating pores on a cell membrane through electric pulses.
The efficiency is determined by the intensity of the pulses, frequency and duration [132].
Electroporation creates transient permeability of the cell membrane and induces a low level
of inflammation at the injection site, facilitating DNA uptake by parenchyma cells and anti‐
gen-presenting cells [133]. As drawbacks, the number of cells transfected is low, and surgery
is required to reach internal organs. This method has been clinically tested for DNA-based
vaccination [134] and for cancer treatment [135].
3.3.4. Sonoporation
Sonoporation utilizes ultrasound to temporally permeabilize the cell membrane to allow cel‐
lular uptake of DNA. It is non-invasive and site-specific and could make it possible to destroy
tumor cells after systemic delivery, while leave non-targeted organs unaffected [13]. Gene de‐
livery efficiency seems to be dependent on the intensisty of the pulses, frequency and dura‐
tion [87]. This method has been applied in the brain, cornea, kidney, peritoneal cavity, muscle,
and heart, among others. Low-intensity ultrasonund in combination with microbubbles has
recently acquired much attention as a safe method of gene delivery [13]. The use of microbub‐
bles as gene vectors is based on the hypothesis that destruction of DNA-loaded microbubbles
by a focused ultrasound beam during their microvascular transit through the target area will
result in localized transduction upon disruption of the microbubble shell while sparing non‐
targeted areas. The therapeutic effect of ultrasound-targeted microbubble destruction is rela‐
tive to the size, stability, and targeting function of microbubbles.
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3.3.5. Photoporation
The photoporation method utilizes a single laser pulse as the physical force to generate tran‐
sient pores on a cell membrane to allow DNA to enter [87]. Efficiency seems to be controlled
by the size of the focal point and pulse frequency of the laser. The level of transgene expres‐
sion reported is similar to that of electroporation. Further studies are needed before this
highly sophisticted procedure becomes a practical technique for gene delivery.
3.3.6. Magnetofection
This method employs a magnetic field to promote transfection. DNA is complexed with
magnetic nanoparticles made of iron oxide and coated with cationic lipids or polymers
through electrostatic interaction. The magnetic particles are then concentrated on the target
cells by the influence of an external magnetic field. Similar to the mechanism of non-viral
vector-based gene delivery, the cellular uptake of DNA is due to endocytosis and pinocyto‐
sis [136]. This method has been successfully applied to a wide range of primary cells, and
cells that are difficult to transfect by other non-viral vectors [137].
3.3.7. Hydroporation
Hydroporation, also called hydrodynamic gene delivery method, is the most commonly
method used for gene delivery to hepatocytes in rodents. Intrahepatic gene delivery is ach‐
ieved by a rapid injection of a large volume of DNA solution via the tail vein in rodents, that
results in a transient enlargement of fenestrae, generation of a transient membrane defect on
the plasma membrane and gene transfer to hepatocytes [87]. This method has been frequent‐
ly employed in gene therapy research. In order to apply this simple method of gene admin‐
istration to the clinic, efforts have been made to reduce the injection volume and avoid
tissue damage.
4. Strategies to improve transfection mediated by non-viral vectors
The successful delivery of therapeutic genes to the desired target cells and their availability
at the intracellular site of action are crucial requirements for efficient gene therapy. The de‐
sign of safe and efficient non-viral vectors depends mainly on our understanding of the
mechanisms involved in the cellular uptake and intracellular disposition of the therapeutic
genes as well as their carriers. Moreover, they have to overcome the difficulties after “in
vivo” administration.
4.1. Target cell uptake and intracellular trafficking
Nucleic acid must be internalized to interact with the intracellular machinery to execute
their effect. The positive surface charge of unshielded complexes facilitates cellular internali‐
zation. The non-viral vector can be functionalized with compounds that are recognized by
the desire specific target cell type. Peptides, proteins, carbohydrates and small molecules
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have been used to induce target cell-specific internalization [138]. For instance, SLN have
been combined with peptides that show penetrating properties, such as the dimeric HIV-1
TAT (Trans-Activator of Transcription) peptide [139] or the synthetic SAP (Sweet Arrow
Peptide) [19].
Endocytosis has been postulated as the main entry mechanism for non-viral systems. Vari‐
ous endocytosis mechanisms have been described to date: phagocytosis, pinocytosis, cla‐
thrin-mediated endocytosis, caveolae/raft-mediated endocytosis and chathrin and caveolae
independent endocytosis. Clathrin-mediated endocytosis leads to an intracellular pathway
in which endosomes fuse with lysosomes, which degrade their content, whereas caveolae/
raft-mediated endocytosis avoids the lysosomal pathway and its consequent vector degra‐
dation [20]. Cytosolic delivery from either endosomes or lisosomes has been reported a ma‐
jor limitation in transfection [140]. In consequence, some research groups have used
substances that facilitate endosomal escape before lysosomal degradation. For clathrin-
mediated endocytosis, the drop in pH is a useful strategy for endosomal scape via proton
destabilization conferred by the cationic carrier, or by pH-dependent activation of mem‐
brane disruptive helper molecules, such as DOPE or fusogenic peptides [141-143]. More re‐
cently, Leung et al. [144] have patented lipids with 4-amino-butiric acid (FAB) as headgroup
to form lipid nanoparticles able to introduce nucleic acids, specifically siRNA, into mamma‐
lian cells. FAB lipids also demonstrated membrane destabilizing properties.
Once genes are delivered in the cytoplasm they have to diffuse toward the nuclear region.
DNA plasmids have difficulties to diffuse in the cytoplasm because they are large in size.
Therefore, packaging and complexing them into small particles facilitates its displacement
intracellularly. Diffusion is a function of diameter; hence, smaller particles move faster than
larger ones. Thus, another way to optimize gene delivery to the nucleus would be to de‐
crease the size of the particles to increase the velocity of passive diffusion through the cyto‐
plasm [145].
The pass through the nuclear membrane is the next step, and it is in general, quite difficult.
There are two mechanisms large molecules can use to overcome that barrier: disruption of
the nuclear membrane during mitosis, which is conditioned by the division rate of targeted
cells, or import through the nuclear pore complex (NPC). This latter mechanism requires
nuclear localization signals, which can be used to improve transfection by non-viral vectors
[146]. In this regard, protamine is a peptide that condenses DNA and presents sequences of
6 consecutive arginine residues [147], which make this peptide able to translocate molecules
such as DNA from the cytoplasm to the nucleus of living cells. Although protamine/DNA
polyplexes are not effective gene vectors [148], the combination of protamine with SLN pro‐
duced good results in both COS-1 and Na 1330 (murine neuroblastoma) culture cells
[149,150]. Precondensation of plasmids with this peptide, to form protamine-DNA com‐
plexes that are later bound to cationic SLN, is another alternative that has shown higher
transfection capacity in retinal cells compared to SLN prepared without protamine [20].
Once inside the nucleus, level of transgene expression depends on the copy number of DNA
and its accessibility for the transcription machinery. Studies have shown that the minimum
number of plasmids delivered to the nucleus required for measurable transgene expression
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depends on the type of vectors [145]. Comparisons between different delivery vehicles
showed that higher copy numbers of DNA molecules in the nucleus do not necessarily cor‐
relate with higher transfection efficiency. At similar plasmid/nucleus copies, lipofectamine
mediated 10-fold higher transfection efficiency than PEI. This suggests that the DNA deliv‐
ered by PEI is biologically less active than the DNA delivered by lipofectamine. It also em‐
phasizes that a deeper understanding of the nuclear events in gene delivery is required for
future progress.
4.2. “In vivo” optimization
Vectors mediating high transfection efficiency “in vitro” often fail to achieve similar results
“in vivo”. One possible reason is that lipidic and polymeric vectors are optimized “in vitro”
using two-dimensional (2D) cultures that lack extracellular “in vivo” barriers and do not re‐
alistically reflect “in vivo” conditions. While cells “in vitro” grow in monolayers, cells “in
vivo” grow in 3D tissue layers held together by the extracellular matrix [145]. This results in
cells with reduced thicknesses but larger widths and lengths. Particles that are taken up di‐
rectly above the nucleus (supranuclear region) have the shortest transport distance to the
nucleus and hence a greater chance of delivery success. The spatiotemporal distribution of
carriers, however, determines the optimal time for endosomal escape and the optimal intra‐
cellular pathway [151]. This highlights the need to develop adequate “in vitro” models that
mimics as much as possible the “in vivo” conditions to optimize carriers for gene therapy.
After intravenous administration, plasma nuclease degradation of the nucleic acid is the first
barrier that needs to be overcome for therapeutic nucleic acid action. Nucleic acids can be
degraded by hydrolytic endo- and exo-nucleases. Both types of nucleases are present in
blood. Therefore, increasing nuclease resistance is crucial for achieving therapeutic effects.
Naked nucleic acids are not only rapidly degraded upon intravenous injection, they are also
cleared from the circulation rapidly, further limiting target tissue localization [138]. To im‐
prove nuclease resistance and colloidal stability, complexation strength is an important fac‐
tor. Shielding the non-viral vectors with poly-L-lysine or poly(ethylene glycol), as
mentioned previously, prolongs the circulation time in blood of the vectors.
Vectors delivered “in vivo” by systemic administration not only have to withstand the
bloodstream, but also have to overcome the cellular matrix to reach all cell layers of the tis‐
sue. While large particles seem to have an advantage “in vitro” due to a sedimentation effect
on cells, efficient delivery of particles deep into organs requires particles <100 nm. Small
particles (40 nm) diffuse faster and more effectively in the extracellular matrix and inner lay‐
ers of tissues, whereas larger particles (>100 nm) are restricted by steric hindrance [152].
The net cationic charge of the synthetic vector is a determinant of circulation time, tissue dis‐
tribution and cellular uptake of synthetic vectors by inducing interactions with negatively
blood constituents, such as erythrocytes and proteins. The opsonisation of foreign particles
by plasma proteins actually represents one of the steps in the natural process of removal of
foreign particles by the innate immune system [153]. This may result in obstruction of small
capillaries, possibly leading to serious complication, such as pulmonary embolism [154].
Part of the complexes end up in the reticuoloendothelial system (RES), where they are re‐
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moved rapidly by phagocytosis or by trapping in fine capillary beds [155]. The nanocarriers,
when circulating in blood, can activate the complement system and it seems that the com‐
plement activation is higher as the surface charge increases [156,157].
The interaction with blood components is related to the intrinsic properties of the cationic
compound (side chain end groups, its spatial conformation and molecular weight), as well
as the applied Nitrogen:Phosphate (N:P) ratio [138]. Shielding of the positive surface charge
of complexes is currently an important strategy to circumvent the aforementioned problems.
The most popular strategy is based on the attachment of water-soluble, neutral, flexible pol‐
ymers, as poly(ethylene glycol), poly(vinylpyrrolidone) and poly(hydroxyethyl-L-aspara‐
gine). The efficacy of the shielding effect of these polymers is determined by the molecular
weight and grafting density of the shielding polymer [158]. Longer chains are usually more
effective in protecting the particle (surface) from aggregation and opsonisation.
The nanocarriers must arrive to the target tissue to exert their action. Although most common‐
ly used targeting strategies consist of proteins and peptides, carbohydrates have also been uti‐
lized [159]. The access of non-viral vector to tumors has been investigated extensively. The
discontinuous endothelial cell layer has gaps that give the nanocarriers the opportunity to es‐
cape the vascular bed and migrate into the tumoral mass. The most common entities used for
tumor targeting include transferrin, epidermal growth factor, and the integrin-binding tri-
peptide arginine-glycine-aspartic acid (RGD) [159]. Brain targeting has also a great interest;
most gene vector do not cross the blood-brain barrier (BBB) after intravenous administration
and must be administered through intracerebral injection, which is highly invasive and does
not allow for delivery of the gene to other areas of the brain. Injection in the cerebrospinal flu‐
id is also another strategy. Commonly used ligands for mediated uptake are insuline-like
growth factors, transferrin or low-density lipid protein [159]. Targeting to the liver has been
also investigated in a great extension by many researchers. Carbohydrate-related molecules,
such as galactose, asialofetuin, N-acetylgalactosamine and folic acid are the most commonly
molecules used for liver targeting [159]. Targeting to endothelial cells provides avenues for
improvement of specificity and effectiveness of treatment of many diseases, such as cardio‐
vascular or metabolic diseases [160]. Among other endothelial cell surface determinants, in‐
tercellular  adhesion  molecule-1  (CD54  or  ICA-1,  a  110-KDa  Ig-like  transmembrane
constitutive endothelial adhesion molecule) is a good candidate target for this goal. ICAM-1
targeting can be achieved by coupling Anti-ICAM-1 antibodies to carriers [161].
5. Conclusion
The success of gene therapy is highly dependent on the delivery vector. Viral vectors have
dominated the clinical trials in gene therapy for its relatively high delivery efficiency. How‐
ever, the improvement of efficacy of non-viral vectors has lead to an increased number of
products entering into clinical trials. A better understanding of the mechanisms governing
the efficiency of transfection, from the formation of the complexes to their intracellular de‐
livery, will lead to the design of better adapted non-viral vectors for gene therapy applica‐
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tions. A number of potentially rate-limiting steps in the processes of non-viral-mediated
gene delivery have been identified, which include the efficiency of cell surface association,
internalization, release of gene from intracellular compartments such as endosomes, transfer
via the cytosol and translocation into the nucleus and transcription efficacy. Insight into mo‐
lecular features of each of these steps is essential in order to determine their effectiveness as
a barrier and to identify means of overcoming these hurdles. Although non-viral vectors
may work reasonably well “in vitro”, clinical success is still far from ideal. Considering the
number of research groups that focus their investigations on the development of new vec‐
tors for gene therapy, together with the advances in the development of new technologies to
better understand their “in vitro” and “in vivo” behavior, the present limitations of non-vi‐
ral vectors will be resolved rationally.
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